skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies

Original Research

(2979) Views  (1217) Full article downloads

Authors: Eric Bateman, Dave Singh, David Smith, et al

Published Date June 2010 Volume 2010:5 Pages 197 - 208
DOI: http://dx.doi.org/10.2147/COPD.S9616

Eric Bateman1, Dave Singh2, David Smith3, Bernd Disse4, Lesley Towse5, Dan Massey5, Jon Blatchford5, Demetri Pavia5, Rick Hodder6

1Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa; 2University Hospital of South Manchester Foundation Trust, University of Manchester, Manchester, UK; 3North Bristol Lung Centre, Southmead Hospital, Bristol, UK; 4Boehringer Ingelheim, GmbH, Ingelheim, Germany; 5Boehringer Ingelheim, Ltd., Bracknell, Berkshire, UK; 6Divisions of Pulmonary and Critical Care Medicine, University of Ottawa, Ottawa, Ontario, Canada

Abstract: Two 1-year studies evaluated the long-term efficacy and safety of tiotropium 5 or 10 μg versus placebo, inhaled via the Respimat® Soft MistTM Inhaler (SMI). The two studies were combined and had 4 co-primary endpoints (trough FEV1 response, Mahler Transition Dyspnea Index [TDI] and St George’s Respiratory Questionnaire scores all at week 48, and COPD exacerbations per patient-year). A total of 1990 patients with COPD participated (mean FEV1: 1.09 L). The mean trough FEV1 response of tiotropium 5 or 10 μg relative to placebo was 127 or 150 mL, respectively (both P < 0.0001). The COPD exacerbation rate was significantly lower with tiotropium 5 μg (RR = 0.78; P = 0.002) and tiotropium 10 μg (RR = 0.73; P = 0.0008); the health-related quality of life and Mahler TDI co-primary endpoints were significantly improved with both doses (both P < 0.0001). Adverse events were generally balanced except anticholinergic class effects, which were more frequent with active treatment. Fatal events occurred in 2.4% (5 μg), 2.7% (10 μg), and 1.6% (placebo) of patients; these differences were not significant. Tiotropium Respimat® SMI 5 μg demonstrated sustained improvements in patients with COPD relative to placebo and similar to the 10 μg dose but with a lower frequency of anticholinergic adverse events.

Keywords: COPD, exacerbations, FEV1, quality of life, Respimat®, tiotropium






 

Other articles by Dr Phillips



Readers of this article also read:

Asthma patients prefer Respimat® Soft Mist™ Inhaler to Turbuhaler®
Modified BODE indexes: Agreement between multidimensional prognostic systems based on oxygen uptake
A day at a time: caregiving on the edge in advanced COPD
The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease
Changes in six-minute walking distance during pulmonary rehabilitation in patients with COPD and in healthy subjects
COPD and cognitive impairment: the role of hypoxemia and oxygen therapy
Tiotropium bromide inhibits TGF-ß-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro
Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
  • Journal Indexing

    See where all the Dove Press journals are indexed

  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio